Lilly ghost-wrote articles to market drug, files say.
Lilly isn't the only drugmaker to use ghostwriters to win favorable play in medical journals. Merck & Co. (Whitehouse Station NJ) and Pfizer Inc. (New York) also have faced claims they used ghostwriters as part of their marketing plans. In May 2008, Merck agreed to pay $58 million to 29 states and stop ghostwriting articles to resolve claims that its advertisements for the withdrawn painkiller Vioxx hid the drug's health risks. Pfizer paid $60 million to 33 states in October to settle claims it improperly marketed its Bextra and Celebrex pain relievers. Pfizer agreed to halt off-label marketing of the medicines and stop ghostwriting about them. It withdrew Bextra in April 2005. Celebrex is still on the market. The Lilly case is UFCW Local 1776 and Participating Employers Health and Welfare Fund v. Eli Lilly & Co., 05-04115, U.S. District Court for the Eastern District of New York (Brooklyn).
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CORPORATE; Eli Lilly & Co.|
|Date:||Jun 15, 2009|
|Previous Article:||Federal Trade Commission.|
|Next Article:||Prizer eyes partnerships, acquisitions in generics.|